抗HBV药物的研制进展及方向

冷雪君; 张莹; 申姣春; 颜学兵

doi:10.3969/j.issn.1001-5256.2016.06.043

抗HBV药物的研制进展及方向

DOI: 10.3969/j.issn.1001-5256.2016.06.043

徐州医学院附属医院感染性疾病科

基金项目:

国家自然科学基金(81371867)；江苏省医学科技专项-新型临床诊疗技术攻关(BL2014033)；江苏省“科教兴卫”医学重点人才培养基金(RC2011117)；江苏省“六大人才高峰”项目(NO2011-WS-068)；

详细信息

中图分类号: R978.7
计量
- 文章访问数: 180
- HTML全文浏览量: 28
- PDF下载量: 325
- 被引次数: 0
出版历程
- 出版日期: 2016-06-20

Direction and progress in research and development of anti-HBV drugs

Research funding:

摘要

摘要: 慢性乙型肝炎(CHB)是全球公众健康的首要危险因素,并且是潜在疾病进展为肝硬化和肝细胞癌(HCC)的主要病因。但迄今为止治疗这种致死性病毒感染的方法却极少,且治疗效果尚不理想。目前人们已经意识到发展新型药物的必要性,综述了目前市场上所有可用的及处于临床试验的药物,介绍了每类抗HBV药物中未来发展前景可能可观的几种治疗药物。指出未来抗HBV药物多效联合用药的发展方向,并为HBV研究者或从事卫生保健工作的专家提供最新的HBV治疗进展。
- 肝炎病毒,乙型 /
- 抗病毒药 /
- 综述
Abstract: Chronic hepatitis B(CHB) is considered as the most important risk factor for public health around the world,as well as the main reason for potential diseases to develop into liver cirrhosis and hepatocellular carcinoma.However up to now,there are few methods for the treatment of this lethal viral infection with poor therapeutic effects.At present,we have realized the necessity to develop new drugs.This article reviews the drugs currently available in market or under clinical trials,introduces several drugs with a promising future in each category of anti- HBV drugs,and points out the developmental direction of multi- effect combination of anti- HBV drugs in future,in order to provide the latest advances in HBV treatment for researchers working on HBV and experts engaged in healthcare.
- hepatitis B virus /
- antiviral agents /
- review

HTML全文

参考文献(16)

[1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatits B:a 2015 update[J].J Clin Hapetol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.

[2]MANZOOR S,SAALIM M,IMRAN M,et al.Hepatitis B virus therapy:what’s the future holding for us:the future[J].World JGastroenterol,2015,21(44):12558-12575.

[3] Hepatits B foundation drug watch.Compounds in development for chronic hepatitis B[EB/OL].(2016-03-25)http://www.hepb.org/professionals/hbf_drug_watch.htm.

[4]PREZ-CAMEO C,PONS M,ESTEBAN R.New therapeutic perspectives in HBV:when to stop NAs[J].Liver Int,2014,34(1):146-153.

[5]YANG FQ,RAO GR.Research progress of therapeutic vaccines against hepatitis B[J].Infect Dis Info,2015,28(2):65-69.(in Chinese)杨富强,饶桂荣.乙型肝炎治疗性疫苗研究进展[J].传染病信息,2015,28(2):65-69.

[6] XUE M,FAN F,DING L,et al.An autophagosome-based therapeutic vaccine for HBV infection:a preclinical evaluation[J].JTransl Med,2014,12:361.

[7]WANG JZ,YANG DL.Immune modulation treatment of chronic hepatits B virus infection[J].Chin J Hepatol,2015,23(3):227-230.(in Chinese)王俊忠,杨东亮.免疫调节治疗慢性乙型肝炎病毒感染的研究进展[J].中华肝脏病杂志,2015,23(3):227-230.

[8]MARTIN P,DUBOIS C,JACQUIER E,et al.TG1050,an immunotherapeutic to treat chronic hepatitis B,induces robust T cells and exerts an antiviral effect in HBV-persistent mice[J].Gut,2015,64(12):1961-1971.

[9]GANE EJ,LIM YS,GORDON SC,et al.The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection[J].J Hepatol,2015,63(2):320-328.

[10]LANFORD RE,GUERRA B,CHAVEZ D,et al.GS-9620,an oral agonist of Toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees[J].Gastroenterology,2013,144(7):1508-1517.

[11]BILLIOUD G,PICHOUD C,PUERSTINGER G,et al.The main hepatitis B virus(HBV)mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication[J].Antiviral Res,2011,92(2):271-276.

[12]WU G,LIU B,ZHANG Y,et al.Preclinical characterization of GLS4,an inhibitor of hepatitis B virus core particle assembly.[J].Antimicrob Agents Chemother,2013,57(11):5344-5354.

[13]WU Y,HAN L,YUAN YF.Meta-analysis of telbivudine and lamivudine in the treatment of chronic hepatitis B[J].China Med Herald,2014,11(28):11-13,18.(in Chinese)吴岩,韩璐,原永芳.替比夫定和拉米夫定治疗慢性乙型肝炎的Meta分析[J].中国医药导报,2014,11(28):11-13,18.

[14]WANG J.Efficacy of lamivudine combined with adefovir dipivoxil in treatment of chronic hepatitis B cirrhosis[J].J Clin Exp Med,2014,13(6):498-500.(in Chinese)王婧.拉米夫定联合阿德福韦酯治疗慢性乙型肝炎肝硬化的疗效观察[J].临床和实验医学杂志,2014,13(6):498-500.

[15] YANG HC,KAO JH.HBV cure-can we pin our hopes on immunotherapy?[J].Nat Rev Gastroenterol Hepatol,2015,12(3):129-131.

[16]LIN CL,YANG HC,KAO JH.Hepatitis B virus:new therapeutic perspectives[J].Liver Int,2016,36(1):85-92.

施引文献

资源附件(0)

访问统计